Research Article| Volume 21, ISSUE 2, P255-259, March 2022

CivaSheet intraoperative radiation therapy for pancreatic cancer

Published:January 12, 2022DOI:


      The treatment of borderline resectable (BR) pancreatic cancer is challenging and requires a multidisciplinary approach with chemotherapy, radiation and surgical resection. Despite using chemotherapy and radiotherapy in the neoadjuvant setting, achievement of negative surgical margins remains technically challenging. Positive margins are associated with increased local recurrences and worse overall survival and there are no standard options for treatment.
      The CivaSheet is an FDA-cleared implantable sheet with a matrix of unidirectional planar low-dose-rate (LDR) Palladium-103 (Pd-103) sources. The sources are shielded on one side with gold to spare radio-sensitive structures such as the bowel. The sheet can easily be customized and implanted at the time of surgery when there is concern for close or positive margins.
      The CivaSheet provides an interesting solution to target the region of close/positive margins after pancreatectomy. Here we discuss the physical properties, the dosimetry, clinical workflow and early patient outcomes with the CivaSheet in pancreatic cancer.


      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to Brachytherapy
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Lekka K.
        • Tzitzi E.
        • Giakoustidis A.
        • et al.
        Contemporary management of borderline resectable pancreatic ductal adenocarcinoma.
        Ann Hepatobiliary Pancreat Surg. 2019; 23: 97
        • Denbo J.W.
        • Fleming J.B.
        Definition and management of borderline resectable pancreatic cancer.
        Surg Clin North Am. 2016; 96: 1337-1350
        • Toesca D.A.S.
        • Koong A.J.
        • Poultsides G.A.
        • et al.
        Management of borderline resectable pancreatic cancer.
        Int J Radiat Oncol Biol Phys. 2018; 100: 1155-1174
        • Kommalapati A.
        • Tella S.H.
        • Goyal G.
        • et al.
        Contemporary management of localized resectable pancreatic cancer.
        Cancers (Basel). 2018; 10
        • Gnerlich J.L.
        • Luka S.R.
        • Deshpande A.D.
        • et al.
        Microscopic margins and patterns of treatment failure in resected pancreatic adenocarcinoma.
        Arch Surg. 2012; 147: 753-760
        • Westgaard A.
        • Tafjord C.
        • Farstad IN
        • et al.
        Resectable adenocarcinomas in the pancreatic head: the retroperitoneal resection margin is an independent prognostic factor.
        BMC Cancer. 2008; 8
        • Verbeke C.S.
        Resection margins and R1 rates in pancreatic cancer—are we there yet?.
        Histopathology. 2008; 52: 787-796
        • Esposito I.
        • Kleeff J.
        • Bergmann F.
        • et al.
        Most pancreatic cancer resections are R1 resections.
        Ann Surg Oncol. 2008; 15: 1651-1660
        • Kim K.S.
        • Kwon J.
        • Kim K.
        • Chie E.K.
        Impact of resection margin distance on survival of pancreatic cancer: a systematic review and meta-analysis.
        Cancer Res Treat. 2017; 49: 824-833
        • Chandrasegaram M.D.
        • Goldstein D.
        • Simes J.
        • et al.
        Meta-analysis of radical resection rates and margin assessment in pancreatic cancer.
        Br J Surg. 2015; 102: 1459-1472
        • Tempero M.A.
        • Malafa M.P.
        • Al-Hawary M.
        • et al.
        Pancreatic adenocarcinoma, Version 2.2021.
        JNCCN J Natl Compr Cancer Netw. 2021; 19: 439-457
      1. Tuli R., Osipov A., Rutgers J.K., et al. Margin distance in resected pancreatic cancer independently predicts survival: implications for adjuvant radiation therapy using pelvic bone marrow hounsfield units to predict cytopenia during anal cancer chemoradiation E214. Int J Radiat Oncol Biol Phys. 2016;96(2S):E214. doi:10.1016/j.ijrobp.2016.06.1128

      2. A directional 103Pd brachytherapy device: dosimetric characterization and practical aspects for clinical use | Elsevier Enhanced Reader. Available at: Accessed August 23, 2021.

        • Cohen G.N.
        • Episcopia K.
        • Lim S.B.
        • et al.
        Intraoperative implantation of a mesh of directional palladium sources (CivaSheet): dosimetry verification, clinical commissioning, dose specification, and preliminary experience.
        Brachytherapy. 2017; 16: 1257-1264
        • Dault J.B.
        • Todor D.
        • Kaplan B.J.
        • et al.
        First report on the feasibility of a permanently implantable uni-directional planar low dose rate brachytherapy sheet for patients with resectable or borderline resectable pancreatic cancer.
        Brachytherapy. 2021; 20: 207-217
      3. Seneviratne D., McLaughlin C., Todor D., et al The CivaSheet: the new frontier of intraoperative radiation therapy or a pricier alternative to LDR brachytherapy? Adv Radiat Oncol. 2017;3(1):87–91. doi:10.1016/j.adro.2017.10.005